1.
Urologe A
; 43(10): 1271-4, 2004 Oct.
Article
in German
| MEDLINE
| ID: mdl-15372156
ABSTRACT
Therapy of metastasized renal cell carcinoma is based on systemic immunotherapeutic strategies, if surgical resection is not possible. The costs of inhalative Interleukin-2 therapy in case of pulmonary metastases as off-label-use are not accepted by compulsory health insurance yet.We report on a female patient with pulmonary metastasized renal cell carcinoma who had tumor progression after immunochemotherapy that followed complete response after inhalative therapy with Interleukin-2.
Subject(s)
Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/secondary , Interleukin-2/administration & dosage , Kidney Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Administration, Inhalation , Adult , Antineoplastic Agents/administration & dosage , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/therapy , Female , Humans , Immunotherapy/methods , Kidney Neoplasms/diagnosis , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Remission Induction/methods , Treatment Failure , Treatment Outcome
2.
Urologe A
; 43 Suppl 3: S133-5, 2004 Sep.
Article
in English
| MEDLINE
| ID: mdl-15179552
Subject(s)
Carcinoma, Renal Cell/immunology , Immunity, Innate/immunology , Kidney Neoplasms/immunology , Killer Cells, Natural/immunology , Lymphocytes, Tumor-Infiltrating/immunology , T-Lymphocytes, Cytotoxic/immunology , Cell Line, Tumor , Humans , Killer Cells, Lymphokine-Activated/immunology , Major Histocompatibility Complex/immunology , Receptors, Antigen, T-Cell/immunology , Tumor Escape/immunology
3.
Cytogenet Cell Genet
; 90(3-4): 246-7, 2000.
Article
in English
| MEDLINE
| ID: mdl-11124526
